Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

Related Citations for PubMed (Select 22338019)

1.

The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?

Postow MA, Callahan MK, Wolchok JD.

Clin Cancer Res. 2012 Apr 1;18(7):1821-3. doi: 10.1158/1078-0432.CCR-12-0409. Epub 2012 Feb 15.

2.

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P.

Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21930211
3.

Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.

Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, Assi H, Berman D, Siegel J, Weber JS.

J Immunother. 2012 Jan;35(1):73-7. doi: 10.1097/CJI.0b013e31823735d6.

PMID:
22130164
4.

Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.

Minutilli E, Feliciani C.

Tumori. 2012 Mar-Apr;98(2):185-90. doi: 10.1700/1088.11928. Review.

PMID:
22677983
5.

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.

Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ.

Clin Cancer Res. 2012 Apr 1;18(7):2039-47. doi: 10.1158/1078-0432.CCR-11-1823. Epub 2012 Jan 23.

6.

Update on the role of ipilimumab in melanoma and first data on new combination therapies.

Maio M, Di Giacomo AM, Robert C, Eggermont AM.

Curr Opin Oncol. 2013 Mar;25(2):166-72. doi: 10.1097/CCO.0b013e32835dae4f. Review.

PMID:
23299197
7.

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS.

Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16.

PMID:
20082117
8.

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S; MDX010-20 Investigators.

Ann Oncol. 2013 Oct;24(10):2694-8. doi: 10.1093/annonc/mdt291. Epub 2013 Aug 13.

9.

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

Pennock GK, Waterfield W, Wolchok JD.

Am J Clin Oncol. 2012 Dec;35(6):606-11. doi: 10.1097/COC.0b013e318209cda9. Review.

PMID:
21336089
10.

Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.

Boasberg P, Hamid O, O'Day S.

Semin Oncol. 2010 Oct;37(5):440-9. doi: 10.1053/j.seminoncol.2010.09.004. Review.

PMID:
21074058
11.

Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.

Lens M, Testori A, Ferucci PF.

Curr Top Med Chem. 2012;12(1):61-6. Review.

PMID:
22196270
12.

GM-CSF/Ipilimumab combination extends melanoma survival.

[No authors listed]

Cancer Discov. 2013 Jul;3(7):OF6. doi: 10.1158/2159-8290.CD-NB2013-083. Epub 2013 Jun 6.

13.

[Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].

Lotem M, Merims S, Frank S, Ospovat I, Peretz T.

Harefuah. 2012 Oct;151(10):585-8, 604. Review. Hebrew.

PMID:
23316667
14.

CTLA-4 antibodies: new directions, new combinations.

Funt SA, Page DB, Wolchok JD, Postow MA.

Oncology (Williston Park). 2014 Nov;28 Suppl 3:6-14. Review.

15.

From ASCO-targeted therapies: Anti-PD-1 approaches--important steps forward in metastatic melanoma.

Razzak M.

Nat Rev Clin Oncol. 2013 Jul;10(7):365. doi: 10.1038/nrclinonc.2013.98. Epub 2013 Jun 11. No abstract available.

PMID:
23752732
16.

Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.

Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G.

J Immunother. 2012 May;35(4):344-53. doi: 10.1097/CJI.0b013e318253ec25.

PMID:
22495392
17.

Combination checkpoint blockade--taking melanoma immunotherapy to the next level.

Riley JL.

N Engl J Med. 2013 Jul 11;369(2):187-9. doi: 10.1056/NEJMe1305484. Epub 2013 Jun 2. No abstract available.

PMID:
23724866
18.

T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.

Del Vecchio M, Mortarini R, Tragni G, Di Guardo L, Bersani I, Di Tolla G, Agustoni F, Colonna V, Weber JS, Anichini A.

J Clin Oncol. 2011 Nov 10;29(32):e783-8. doi: 10.1200/JCO.2011.36.5957. Epub 2011 Oct 11. No abstract available.

19.

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Weber J.

Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Review.

20.

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13.

PMID:
19139884
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk